Microbiome Acquisition and Progression of Inflammation and Airway Disease in Infants and Children With Cystic Fibrosis


Cystic Fibrosis

What is the purpose of this trial?

Cystic Fibrosis (CF) is a fatal, recessive genetic disorder characterized by progressive inflammation and lung damage. It is unclear whether current treatment strategies, which focus on detection and eradication of pathogenic microorganisms in the lung, are the best way to prevent the initiation of early inflammation and lung damage. This study asks how early acquisition of microbial flora occurs in infants with CF and healthy baby controls, and whether this process initiates or influences early inflammation and clinical disease progression in CF.

Participation Guidelines

3 Months - 4 Years

Click here for detailed information about who can participate in this trial.

Yale University
August 2012
Last Updated:
June 12, 2014
Study HIC#:

Clinicaltrials.gov ID: NCT01661491